Ojjaara
Payments companies reported to CMS as associated with Ojjaara. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Ojjaara, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Ojjaara
These are the largest totals companies reported as associated with Ojjaara. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| James Mccloskey | Hackensack, NJ | Medical Oncology | $249,269.13 |
| Devesh Pandya | Houston, TX | Hematology & Oncology | $164,064.01 |
| Mark Davis | Fort Worth, TX | Medical | $122,417.55 |
| George Yaghmour | Los Angeles, CA | Hematology & Oncology | $98,641.42 |
| Melhem Solh | Atlanta, GA | $93,110.93 | |
| Zohra Nooruddin | San Antonio, TX | Medical Oncology | $88,838.84 |
| Raji Shameem | Orlando, FL | Medical Oncology | $86,276.91 |
| Radhakrishnan Ramchandren | West Reading, PA | Hematology (Internal Medicine) | $86,038.88 |
| Salman Fazal | Pittsburgh, PA | Hematology & Oncology | $85,088.81 |
| Jarrod Holmes | Santa Rosa, CA | Hematology & Oncology | $79,317.61 |
Prescribed Ojjaara?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.